| Enzastaurin - Wikipedia, the free encyclopedia Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein ... Read More |
| Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse ... Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Oral Agent Designed to Address High Incidence of Relapse in DLBCL ... Read More |
| Enzastaurin (LY317615) | PKC Inhibitor | Buy Enzastaurin (LY317615 ... Enzastaurin (LY317615) is a potent PKC beta inhibitor for PKCβ, PKCα, PKCγ and PKCε with IC50 of 6, 39, 83 and 110 nM, respectively. Order Enzastaurin (LY317615 ... Read More |
| Enzastaurin. - National Center for Biotechnology Information 1. Expert Opin Investig Drugs. 2008 Jun;17(6):939-44. Enzastaurin. Chen YB, LaCasce AS. Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 ... Read More |
| Targeted, Oral Agent Enzastaurin Shows Favorable Results In Late ... Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non ... Read More |
| Targeted, oral agent Enzastaurin shows favorable results The data presented were gathered from a multicenter Phase II study of enzastaurin as a second- or third-line treatment of NSCLC (ASCO Abstract #7543 ). The rationale ... Read More |
| Enzastaurin Side Effects | LIVESTRONG.COM Enzastaurin Side Effects. Enzastaurin hydrochloride is an anti-cancer drug developed by Eli Lily and Company that is currently in phase III clinical trials. It acts ... Read More |
| Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits ... Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines Read More |
| Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its ... Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer Read More |
| Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late ... Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer Study Supports Lilly's Commitment to Advances in Lung Cancer Treatment Read More |
